|
Description of the route of administration for each institutions preferred agent |
||
| Agent |
Administration route |
n |
|
|
||
| Histamine-2-antagonist |
Intermittent IV |
63 |
| IV infusion |
13 |
|
| Oral |
27 |
|
| Feeding tube |
36 |
|
| Sucralfate |
Oral |
13 |
| Nasogastric tube |
20 |
|
| Omeprazole |
Oral |
4 |
| Nasogastric tube |
4 |
|
| Enteral tube |
2 |
|
| Other |
0 |
|
|
Responders were permitted to check more than one administrationroute for their institution's preferred agent. IV, intravenous. | ||
Erstad et al. Critical Care 1999 3:145 doi:10.1186/cc368 |
||